0001209191-20-054670.txt : 20201013 0001209191-20-054670.hdr.sgml : 20201013 20201013170057 ACCESSION NUMBER: 0001209191-20-054670 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201009 FILED AS OF DATE: 20201013 DATE AS OF CHANGE: 20201013 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Do Hung CENTRAL INDEX KEY: 0001593353 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 201236997 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-09 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001593353 Do Hung C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512 0 1 0 0 Chief Science Officer Common Stock 2020-10-09 4 M 0 43700 8.61 A 564507 D Common Stock 2020-10-09 4 M 0 75000 12.28 A 639507 D Common Stock 2020-10-09 4 M 0 75000 9.03 A 714507 D Common Stock 2020-10-09 4 S 0 193700 15.0298 D 520807 D Stock Options (right to buy) 8.61 2020-10-09 4 M 0 43700 0.00 D 2025-01-02 Common Stock 43700 0 D Stock Options (right to buy) 12.28 2020-10-09 4 M 0 75000 0.00 D 2025-06-01 Common Stock 75000 0 D Stock Options (right to buy) 9.03 2020-10-09 4 M 0 75000 0.00 D 2026-01-04 Common Stock 75000 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.14 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of October 9, 2020. /s/ Christian Formica, Attorney-in-Fact 2020-10-13